Analysts Set Expectations for ImmunityBio FY2026 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of ImmunityBio in a research note issued to investors on Friday, May 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.28) per share for the year, up from their previous forecast of ($0.32). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.31) per share.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. BTIG Research set a $12.00 price objective on shares of ImmunityBio in a research note on Friday. D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research note on Tuesday, May 5th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

ImmunityBio Trading Up 0.1%

Shares of NASDAQ IBRX opened at $8.12 on Wednesday. The stock has a market cap of $8.50 billion, a price-to-earnings ratio of -9.55 and a beta of 0.02. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43. The company’s 50-day moving average price is $7.92 and its 200 day moving average price is $5.30.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The company had revenue of $44.21 million for the quarter, compared to analysts’ expectations of $43.07 million.

Insider Activity

In related news, Director Barry J. Simon sold 165,000 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. The trade was a 5.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The SEC filing for this sale provides additional information. Insiders sold a total of 275,000 shares of company stock valued at $2,934,500 in the last three months. 69.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its stake in ImmunityBio by 11.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 39,030 shares of the company’s stock valued at $299,000 after purchasing an additional 3,930 shares during the last quarter. Cutler Investment Counsel LLC acquired a new position in ImmunityBio in the 1st quarter valued at about $767,000. Dimensional Fund Advisors LP raised its stake in ImmunityBio by 345.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 110,009 shares of the company’s stock valued at $844,000 after purchasing an additional 85,305 shares during the last quarter. KBC Group NV acquired a new position in ImmunityBio in the 1st quarter valued at about $79,000. Finally, SEB Asset Management AB acquired a new position in ImmunityBio in the 1st quarter valued at about $18,770,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for ImmunityBio and reiterated a Buy rating with a $15 price target, signaling some analyst confidence in the company’s outlook.
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Kessler Topaz, and others, reminded investors that the May 26 lead-plaintiff deadline is approaching in the pending securities class action. Article Title
• Neutral Sentiment: The stock is also being discussed in relation to FDA scrutiny over advertising claims for Anktiva, which is reinforcing uncertainty around the near-term narrative. Article Title
• Negative Sentiment: The securities class action itself is the key negative catalyst, with allegations that ImmunityBio misled investors about drug limitations and efficacy-related claims, adding legal overhang to the stock. Article Title

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.